Loomis, Sayles & Company
TXG icon

Loomis, Sayles & Company’s 10x Genomics TXG Stock Holding History

Loomis, Sayles & Company’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-21
Closed -$2K – 1054
2022
Q1 		$2K Buy
+21
New +$1.84K ﹤0.01% 977
2021
Q2 		– Sell
-79
Closed -$14K – 915
2021
Q1 		$14K Buy
79
+5
+7% +$863 ﹤0.01% 710
2020
Q4 		$10K Buy
+74
New +$10.7K ﹤0.01% 735

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Loomis, Sayles & Company's TXG Position: Q2 2022 in Review

Loomis, Sayles & Company sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 21 shares — an estimated $2K sold.

Loomis, Sayles & Company first reported a position in TXG in Q4 2020 and held it in 3 quarters. The position peaked at $14K in Q1 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • Loomis, Sayles & Company reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 21 10x Genomics shares in Q2 2022, an estimated $2K.
  • Loomis, Sayles & Company first reported a position in 10x Genomics in Q4 2020 and held it in 3 quarters.
  • Loomis, Sayles & Company's 10x Genomics position peaked at $14K in Q1 2021.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Loomis, Sayles & Company's 13F filing for Q2 2022, filed 5 Aug 2022.